Tezepelumab

From WikiMD.org
Jump to navigation Jump to search

Tezepelumab

Tezepelumab (pronounced tez-e-pel-um-ab) is a monoclonal antibody designed for the treatment of asthma, particularly severe asthma that is uncontrolled by standard therapies. It is developed by Amgen and AstraZeneca.

Etymology

The name "Tezepelumab" follows the World Health Organization's guidelines for the naming of monoclonal antibodies. The "-mab" suffix indicates it is a monoclonal antibody, while the "teze-" prefix is likely arbitrary.

Mechanism of Action

Tezepelumab works by blocking the action of a protein called thymic stromal lymphopoietin (TSLP), which is an upstream modulator in the inflammation process of asthma. By inhibiting TSLP, tezepelumab can prevent the release of pro-inflammatory cytokines and chemokines, and thus reduce inflammation and prevent asthma attacks.

Clinical Trials

Tezepelumab has undergone several clinical trials to evaluate its safety and efficacy. In Phase 3 trials, it has shown to significantly reduce the annual asthma exacerbation rate in patients with severe, uncontrolled asthma.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski